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Edited by J. H. NaismithAbstractBiosynthetically and chemically derived analogs of the antibiotic pactamycin and de-6-methylsalicylyl
(MSA)-pactamycin have attracted recent interest as potential antiprotozoal and antitumor drugs. Here, we
report a 3.1-Å crystal structure of de-6-MSA-pactamycin bound to its target site on the Thermus thermophilus
30S ribosomal subunit. Although de-6-MSA-pactamycin lacks the MSAmoiety, it shares the same binding site
as pactamycin and induces a displacement of nucleic acid template bound at the E-site of the 30S. The
structure highlights unique interactions between this pactamycin analog and the ribosome, which paves the
way for therapeutic development of related compounds.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Antibiotics that bind selectively to bacterial or
protozoal ribosomes are of great clinical significance
due to their ability to treat infectious diseases without
compromising the host.1,2 The most effective antibi-
otics used in clinical treatment exploit subtle
differences between distinct locations within the
functional sites of prokaryotic and eukaryotic ribo-
somes. On the other hand, compounds such as
sparsomycin3 and pactamycin,4 which are known to
interact with the ribosome with universal specificity,
have been reported as potential antitumor drugs.
The aminocyclopentitol pactamycin (Fig. 1a) was
first isolated from Streptomyces pactum as a potential
antitumor drug and later found to exhibit potent activity
againstmany bacteria, archaea, and eukaryotes.4,5 In
accordance with biochemical data,6,7 the crystal
structure of pactamycin bound to the 30S ribosomal
subunit revealed that this antibiotic binds near a highly
conserved region of 16SRNAatwhat is now known to
be ribosomal E-site.8 It was therefore proposed that
pactamycin prevents a codon–anticodon interaction
forming at this location and blocks the translocation of
P-site tRNA into the E-site of the 30S.9
The biosynthetic pathway of pactamycin has been
elucidated10 and shown to proceed via an interme-
diate compound, de-6-methylsalicylyl (MSA)-pacta-0022-2836 © 2013 The Authors. Published by Elsevier Ltd.Open access umycin (Fig. 1a). This compound lacks the 6-
methylsalicylic acid ring of the parent molecule and
yet displays equivalent antibacterial and antitumor
activity to pactamycin, suggesting that the 6-methyl-
salicylic acid moiety is not required for cell toxicity.10
Biosynthetic products related to de-6-MSA-pacta-
mycin also inhibit growth of malarial parasites, but
with a significant reduction in toxicity to mammalian
cells.11,12 Likewise, semisynthetic analogs of de-6-
MSA-pactamycin, prepared following the first total
synthesis of pactamycin13 and varying in the nature
of the urea or the aniline moieties, exhibit potent in
vitro antiparasitic and antitumor activity.14 A recent
enantioselective synthesis of pactamycin totaling
only 15 steps will augur well for newer analogs.15,16
Knowing that de-6-MSA-pactamycin maintained its
in vitro antibacterial, antitumor, and antiparasitic
activities, we were particularly interested to see how
the absence of the 6-methylsalicylic acid moiety would
affect its binding to the ribosome. Consequently, we
determined the crystal structure of the Thermus
thermophilus 30S ribosomal subunit bound to de-6-
MSA-pactamycin in the presence of paromomycin,
which enables a detailed description of interactions
between pactamycin analogs and the ribosome.
Following refinement of the initial atomic model, weJ. Mol. Biol. (2013) 425, 3907–3910nder CC BY-NC-ND license.
Fig. 1. Binding of de-6-MSA-pactamycin to the 30S ribosomal subunit. (a) Chemical structure of pactamycin and its
analog de-6-MSA-pactamycin. (b) Location of the de-6-MSA-pactamycin (yellow) binding site on the 30S ribosomal
subunit (cyan) with pactamycin displayed in orange to serve as a reference. The pactamycin-bound conformation of the 3′
end of 16S RNA is also displayed in orange, and the unbiased Fo − Fc difference map is contoured at 3σ. (c) Interaction
distances at the de-6-MSA-pactamycin binding site.
3908 Crystal Structure of Pactamycin Analogunambiguously placed de-6-MSA-pactamycin into
electron density identified at the tip of helix 23b
(Fig. 1b). This location has previously been described
as the binding site of pactamycin.8 The two distal
aromatic rings of pactamycin are known to stack
against each other and G693 of helix 23b due to the
antibiotic adopting a folded structure mimicking an
RNA dinucleotide. This was suggested to result in a
displacement of the E-site mRNA. Similarly, the
remaining aminoacetophenone moiety of de-6-MSA-
pactamycin stacks against the base of G693, where it
is stabilized by O6 and N7 forming hydrogen bonds
with an amine and ketone on the neighboring
cyclopentitol.A superposition of our structure with the empty
30S subunit reveals that, like pactamycin,8 de-6-
MSA-pactamycin prevents the 3′ end of 16S RNA
from folding back on itself to mimic an E-site codon.
However, the absence of a 6-methylsalicylic acid
moiety on de-6-MSA-pactamycin means that the 3′
end of the 16S, and presumably the path of mRNA,
is displaced to a lesser extent than it would be in the
presence of pactamycin (~8.0 Å compared to
~12.5 Å; Fig. 1b). This allows base U1540 of the
16S to form a novel hydrogen bond via its O2 and the
carbonyl group of the aminoacetophenone ring
(interaction 1; Fig. 1c). Interestingly, replacement of
the acetyl group in the aniline moiety of de-6-MSA-
3909Crystal Structure of Pactamycin Analogpactamycin by fluorine or trifluoromethyl results in
potent in vitro antimalarial activity.14 It is likely that a
hydrogen bond is shared between fluorine and
U1540 when such compounds form a complex with
the ribosome.
Further hydrogen bond interactions were identified
between bases G693 and C796 and functional
groups on the extensions of the central ring
(Fig. 1c, interactions 2–6). The N4 of base C795
forms a hydrogen bond with the hydroxyl group on
the C7 cyclopentitol atom (interaction 6; Fig. 1c),
which is absent in the antimalarial analog de-6-
MSA-7-deoxypactamycin. It would therefore appear
that a loss of this hydrogen bond is sufficient to
reduce binding of de-6-MSA-7-deoxypactamycin to
the mammalian ribosome, enough to lower cell
toxicity 10- to 30-fold.12 Together, these interactions
mean that de-6-MSA-pactamycin forms a tightly
bound complex with the ribosome that disrupts
base pairing at the E-site of the 30S subunit.
Although de-6-MSA-pactamycin shares the same
binding site as pactamycin, a new collection of
antibiotic–ribosome contacts distinguishes this deriv-
ative from its parent molecule. A complete under-
standing of such interactions will aid in the design of
newand improvedanalogs toward the development of
effective antiprotozoal and antitumor drugs.Acknowledgements
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